HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?

Ilaria Pennacchia, Fabio Maria Vecchio, Arnaldo Carbone, Vincenzo Arena

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

An accurate determination of human epidermal growth factor receptor 2 (Her2) status in women with breast cancer is mandatory to identify patients who will benefit from trastuzumab-based therapy.
Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalApplied Immunohistochemistry and Molecular Morphology
Volume23
DOIs
Publication statusPublished - 2015

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Breast Neoplasms
  • Cell Membrane
  • Female
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Middle Aged
  • Protein Transport
  • Receptor, ErbB-2
  • Reference Standards
  • Research Design
  • Trastuzumab

Fingerprint

Dive into the research topics of 'HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?'. Together they form a unique fingerprint.

Cite this